Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alto Ingredients, Inc.

1.05
+0.04003.96%
Post-market: 1.050.00000.00%16:50 EDT
Volume:377.02K
Turnover:385.93K
Market Cap:81.07M
PE:-1.29
High:1.10
Open:1.01
Low:0.9700
Close:1.01
Loading ...

Alto Ingredients, Inc. Enters into Letter Agreement with Bradley L. Radoff and Michael Torok

GlobeNewswire
·
18 Mar

Alto Ingredients, Inc.'s (NASDAQ:ALTO) largest shareholders are individual investors with 53% ownership, institutions own 37%

Simply Wall St.
·
10 Mar

Alto Ingredients Price Target Maintained With a $5.50/Share by HC Wainwright & Co.

Dow Jones
·
06 Mar

Alto Ingredients Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
06 Mar

Alto Ingredients Q4 GAAP EPS (0.57) Down from (0.26) YoY, Sales $236.35M Down from $273.625M YoY.

Benzinga
·
06 Mar

BRIEF-Alto Ingredients Q4 EPS USD -0.57

Reuters
·
06 Mar

Alto Ingredients, Inc. Reports Fourth Quarter and Year-end 2024 Results

GlobeNewswire
·
06 Mar

Alto Ingredients, Inc. to Present in the 37th Annual Roth Conference

GlobeNewswire
·
04 Mar

Alto Ingredients Inc expected to post a loss of 11 cents a share - Earnings Preview

Reuters
·
04 Mar

Alto Ingredients (ALTO) Gets a Buy from Craig-Hallum

TIPRANKS
·
28 Feb

Alto Ingredients, Inc. to Release Fourth Quarter and Year-end 2024 Financial Results on March 5, 2025

GlobeNewswire
·
26 Feb

BRIEF-Radoff Bradley Louis Reports About 4.7% Stake In Alto Ingredients

Reuters
·
25 Feb

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Business Wire
·
19 Feb

Promising Outlook for Alto Neuroscience with ALTO-300’s Phase IIb Success Reinforcing Buy Rating

TIPRANKS
·
15 Feb

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

Business Wire
·
12 Feb